NCT04061772

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

A Prospective Study of Bortezomib Combined With CHEP Regimen in the Treatment of Primary Peripheral T Cell Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma

Detailed description

The purpose of this study was to evaluate the efficacy and safety of bortezomib combined with CHEP in patients with peripheral T cell lymphoma. Primary end point of this study were objective response rate including complete remission rate and partial remission rate.

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Bortezomib	Bortezomib injection
DRUG	Etoposide	Etoposide injection
DRUG	Cyclophosphamide	Cyclophosphamide injection
DRUG	Pharmorubicin	Pharmorubicin injection
DRUG	Prednisone	Prednisone tablet

Timeline

• Start date: 2019-08-12
• Primary completion: 2021-07-05
• Completion: 2021-12-05
• First posted: 2019-08-20
• Last updated: 2019-08-20

Locations

1 site across 1 country: China